Rushin Patel MD
117 posts

Rushin Patel MD
@rushin311
Cardiology Fellow @LaheyCardiology @LaheyHospital | Lahey IM alum | Wildlife Photography Enthusiast
















#SGLT2i and #GLP1 are both independently shown to benefit patients with #HFpEF #heartfailure But can #GLP1 provide incremental benefits to those already on #SGLT2i ? The answer is YES ✅️✅️✅️ For patients with #diabetes #HFpEF & #Obesity #realworlddata ➡️ Use of #GLP1 💉 ➕️ #SGLT2i💊 ⏬️ 🫀heart failure exacerbation ⏬️ 🏥 hospitalization & ER visits ⏬️ 💗 atrial fibrillation ⏬️ 🫁 Pulmonary hypertension ⏬️ Renal failure sciencedirect.com/science/articl… @JACCJournals @rushin311 @SaurabhSDani @JavedButler1 @DLBHATTMD @MkosiborodMD @gcfmd @Sadeer_AlKindi @Ashish_Kumar_MD @SumanthKhadkeMD @bhargavv_122 @AmmarWB @MarkWadid

GLP-1 receptor agonist use on top of SGLT2 inhibition in patients with #HFpEF, type 2 diabetes and #obesity was associated with reduced risk for adverse events vs. SGLT2 inhibition alone @ACCinTouch #Cardiotwitter @EndocrineToday @Nephronline Read more👇 healio.com/news/cardiolog…

#Obesity 🔄 #HFpEF SGLT2i & GLP1RA independently benefit HFpEF. However, incremental benefits of both underexplored @JACCJournals study: #GLP1RA ➡️ incremental benefits in addition to #SGLT2i for pts with HFpEF, Obesity & T2DM










Nirmatrelvir plus ritonavir in nonhospitalized vaccinated patients with pre-existing #CVD with #COVID19 were associated with a reduction in PASC and health care utilization. bit.ly/3L5TrsD #JACCAdvances @rushin311 @SarjuGanatraMD



